{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:34:41Z","timestamp":1769729681066,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024150","name":"Sanwa Kagaku Kenkyusho","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aimed to evaluate the factors contributing to insulin dosage adjustment and the risk of sodium\u2010glucose cotransporter\u20102 inhibitor (SGLT2i) discontinuation in persons with type 1 diabetes mellitus (T1DM) starting SGLT2i therapy in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This retrospective study used the electronic medical record\u2010based survey data of 49 patients attending our hospital between December 2018 and October 2021 to investigate the clinical use and adverse effects of SGLT2i in persons with T1DM starting SGLT2i.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Upon <jats:styled-content style=\"fixed-case\">SGLT2i<\/jats:styled-content> initiation, there were five patients in the favorable glycemic control group (<jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\u2009&lt;\u20097.5%) and 44 patients in the poor glycemic control group (<jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\u2009\u2265\u20097.5%); few patients in the favorable glycemic control group reduced total daily insulin dose according to the recommendation, while 75% of patients in the group with poor glycemic control followed the guideline. Moreover, 60% of patients had hypoglycemia before the introduction of <jats:styled-content style=\"fixed-case\">SGLT2i<\/jats:styled-content>; additionally, among patients with no hypoglycemia before introduction, 50% had hypoglycemia after introduction. The group with hypoglycemia after induction tended to have longer diabetes duration and lighter body weight compared to the group without hypoglycemia. Multiple regression analysis revealed that diuretic use was an independent risk factor for discontinuation of <jats:styled-content style=\"fixed-case\">SGLT2i<\/jats:styled-content> (partial regression coefficient\u2009=\u20090.819, <jats:italic>P<\/jats:italic>\u2009=\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>When initiating SGLT2i in T1DM patients, it is important to evaluate glycemic control and adjust insulin dosage based on weight and diabetes duration to reduce hypoglycemia frequency.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.70085","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:09:46Z","timestamp":1748257786000},"page":"1420-1429","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical use and monitoring of adverse effects of sodium\u2010glucose cotransporter\u20102 inhibitors in persons with type 1 diabetes mellitus"],"prefix":"10.1111","volume":"16","author":[{"given":"Chinatsu","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Pharmacy Tokyo Medical University Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2503-9406","authenticated-orcid":false,"given":"Shinichi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology Tokyo Medical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0354-0849","authenticated-orcid":false,"given":"Keiji","family":"Sugai","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology Tokyo Medical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0954-6988","authenticated-orcid":false,"given":"Hironori","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tokyo Medical University Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2965-6906","authenticated-orcid":false,"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology Tokyo Medical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06080616"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13960"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3430"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0078"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-015-0248-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.10.1711"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0161"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13181"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13922"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1749"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00971-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13160"},{"key":"e_1_2_7_15_1","first-page":"1","article-title":"Recommendation on the appropriate use of SGLT2 inhibitors in the treatment of CKD published by the Japanese Society of Nephrology","volume":"65","author":"Fukami K","year":"2023","journal-title":"J Jpn Ren Assoc"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-23-0605"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3169"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2556"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13576"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12882"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13506"},{"key":"e_1_2_7_22_1","first-page":"833","article-title":"Elucidating the actual utilization of pharmaceutical risk management plans (RMPs) in hospital pharmacy departments","volume":"59","author":"Kikuti D","year":"2023","journal-title":"J Jpn Soc Hosp Pharm"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12226993"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045691"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T12:51:00Z","timestamp":1754052660000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.70085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/jdi.70085"],"URL":"https:\/\/doi.org\/10.1111\/jdi.70085","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"2025-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}